Citron Research Out Negative on J2 Global (JCOM)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/28/2026
- S&P 500 ends higher as investors await tech earnings
- NVIDIA’s rising CDS the talk of Wall Street amid circular financing fears
- Market watchers weigh chances of a surprise Fed rate hike tomorrow
- U.S. chip stocks extend losses on AI financing, China competition fears
- Tesla to buy power from Arizona solar project
- Visa (V) To Cut 7% Of Its Workforce, Totaling About 2,600 Jobs - Bloomberg
- BTIG Upgrades Outlook Therapeutics Inc. (OTLK) to Buy
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- Carpenter Technology CEO Brian Malloy passes; Tony Thene returns as CEO
- Applied Digital (APLD) Tops Q4 EPS by 23c, Revenue Beats
Early Valeant/Walgreens Boots Prescription Trends Continuing to Look Positive - Guggenheim (VRX) (WBA)
March 11, 2016 9:37 AM ESTGuggenheim affirms Valeant Pharma (NYSE: VRX) with a Buy rating and $145 price target following recent dermatology prescription performance checks.
Analyst Louise Chen noted the following on Friday:
VRX dermatology Rxs reached ~80% of their levels prior to any disruption from Philidor (October '15) levels up from ~75% last week. TRx's for derm... MoreJ2 Global (JCOM) Comments on Citron Report; Calls 'Factually Incorrect'
March 11, 2016 6:06 AM ESTj2 Global, Inc. (Nasdaq: JCOM). j2 is aware of a report issued yesterday that we believe is both factually incorrect and wrongly... More
UPDATE: Is J2 Global (JCOM) Short a Blast from the Past?
March 10, 2016 2:06 PM EST(Updated - March 10, 2016 3:04 PM EST)
Some traders are suggesting Citron Research was recommending a short on J2 Global (NASDAQ: JCOM) 10 years ago when it was Stocklemon. It is unclear if this is the case. Shares are hitting the lows of the session down 20%... More
